SPDYE1

Across TCGA pan-cancer cohorts, SPDYE1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPDYE1 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher SPDYE1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPDYE1 expression acts as an unfavorable survival marker.

PAAD, KIRC, and SKCM are the cancer types where SPDYE1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.131	0.613	.001	15	view →
KIRC	OS	Median	All	0.144	0.655	.029	12	view →
SKCM	DFS	Median	All	0.219	0.760	.005	6	view →
SARC	DFS	Median	All	0.130	0.632	.045	3	view →
ESCA	DFS	Median	II,III,IV	0.149	0.522	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPDYE1–PAAD (OS)

Open the PAAD breakdown →